Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
8 drugs in development
By Therapeutic Area
top 5
R&D Momentum
69/100
Pipeline Velocity
41/100
Trial Completion Rate
77/100
Pipeline Concentration
27/100
Pipeline Freshness
42/100
Strategic Signals
Activity
Last 14 days
Effect of the Training Toolbox in the Emergency Medecine on Medical Students' Performance in the Objective Structured Clinical Examination in France : a Cluster Randomized Controlled Trial
PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in Non-small Cell Bronchopulmonary Cancer (NSCLC)
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)